Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments

Vaccine

Volumn 26, Issue 35, 2008, Pages 4617-4623

  Anton, Peter A ^a   Ibarrondo, F Javier ^a   Boscardin, W John ^a,b   Zhou, Ying ^a,b   Schwartz, Elissa J ^d   Ng, Hwee L ^a,b   Hausner, Mary Ann ^a   Shih, Roger ^a   Elliott, Julie ^a   Hultin, Patricia M ^a   Hultin, Lance E ^a   Price, Charles ^a   Fuerst, Marie ^e   Adler, Amy ^a   Wong, Johnson T ^c   Yang, Otto O ^a   Jamieson, Beth D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

^e Washington State University ^*  (United States)

Author keywords

HIV; Mucosal immunity; Vaccine

Indexed keywords

GAG PROTEIN; LIVE VACCINE; POL PROTEIN; RECOMBINANT VACCINE; TBC 3B; TBC 3B VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CD8+ T LYMPHOCYTE; DELTOID MUSCLE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL MUCOSA; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IMMUNOGENICITY; INGUINAL REGION; MALAISE; MALE; MONONUCLEAR CELL; MUCOSA; MUCOSAL IMMUNITY; MYALGIA; NORMAL HUMAN; PRIORITY JOURNAL; SIGMOIDOSCOPY; VACCINIA VIRUS;

ADULT; AIDS VACCINES; ANTIBODIES, VIRAL; BLOOD; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV-1; HUMANS; INJECTIONS, SUBCUTANEOUS; INTESTINAL MUCOSA; MALE; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 48649086553     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.084     Document Type: Article

References (39)

1. Lehner T., and Anton P.A. Mucosal immunity and vaccination against HIV. AIDS 16 Suppl. 4 (2002) S125-S132
2. Anton P.A., Elliott J., Poles M.A., McGowan I.M., Matud J., Hultin L.E., et al. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 14 12 (2000) 1761-1765
3. Gurney K.B., Elliott J., Nassanian H., Song C., Soilleux E., McGowan I., et al. Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J Virol 79 9 (2005) 5762-5773
4. Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 6 12 (2006) 930-939
5. Gherardi M.M., and Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 86 Pt 11 (2005) 2925-2936
6. Belyakov I.M., Ahlers J.D., and Berzofsky J.A. Mucosal AIDS vaccines: current status and future directions. Expert Rev Vaccines 3 Suppl. 4 (2004) S65-S73
7. + T-lymphocyte responses in blood and mucosa during chronic infection. J Virol 79 7 (2005) 4289-4297
8. Broliden K., Hinkula J., Devito C., Kiama P., Kimani J., Trabbatoni D., et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 79 1-2 (2001) 29-36
9. Devito C., Hinkula J., Kaul R., Lopalco L., Bwayo J.J., Plummer F., et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 14 13 (2000) 1917-1920
10. +) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 107 10 (2001) 1303-1310
11. Rowland-Jones S.L., Pinheiro S., Kaul R., Hansasuta P., Gillespie G., Dong T., et al. How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection?. Immunol Lett 79 1-2 (2001) 15-20
12. McNicholl J.M., and Promadej N. Insights into the role of host genetic and T-cell factors in resistance to HIV transmission from studies of highly HIV-exposed Thais. Immunol Res 29 1-3 (2004) 161-174
13. Neeson P., Boyer J., Kumar S., Lewis M.G., Mattias L., Veazey R., et al. A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of alpha4beta7 integrin and an effector memory phenotype. Virology 354 2 (2006) 299-315
14. + CTLs in delay of AIDS viral dissemination from mucosa. Blood 107 8 (2006) 3258-3264
15. Vajdy M., Singh M., Kazzaz J., Soenawan E., Ugozzoli M., Zhou F., et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retroviruses 20 11 (2004) 1269-1281
16. Ranasinghe C., Medveczky J.C., Woltring D., Gao K., Thomson S., Coupar B.E., et al. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine 24 31-32 (2006) 5881-5895
17. Sharpe S., Hanke T., Tinsley-Bown A., Dennis M., Dowall S., McMichael A., et al. Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara. Virology 313 1 (2003) 13-21
18. Peacock J.W., Nordone S.K., Jackson S.S., Liao H.X., Letvin N.L., Yafal A.G., et al. Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting. J Virol 78 23 (2004) 13163-13172
19. Lehner T., Wang Y., Cranage M., Bergmeier L.A., Mitchell E., Tao L., et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 2 7 (1996) 767-775
20. Ellenberger D., Otten R.A., Li B., Aidoo M., Rodriguez I.V., Sariol C.A., et al. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology 352 1 (2006) 216-225
21. Buonaguro L., Visciano M.L., Tornesello M.L., Tagliamonte M., Biryahwaho B., and Buonaguro F.M. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 79 11 (2005) 7059-7067
22. Devito C., Zuber B., Schroder U., Benthin R., Okuda K., Broliden K., et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 173 11 (2004) 7078-7089
23. Egan M.A., Chong S.Y., Hagen M., Megati S., Schadeck E.B., Piacente P., et al. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine 22 27-28 (2004) 3774-3788
24. Kutteh W.H., Kantele A., Moldoveanu Z., Crowley-Nowick P.A., and Mestecky J. Induction of specific immune responses in the genital tract of women after oral or rectal immunization and rectal boosting with Salmonella typhi Ty 21a vaccine. J Reprod Immunol 52 1-2 (2001) 61-75
25. Moldoveanu Z., Clements M.L., Prince S.J., Murphy B.R., and Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 13 11 (1995) 1006-1012
26. + T-cell epitopes. J Virol 80 10 (2006) 4717-4728
27. Cebere I., Dorrell L., McShane H., Simmons A., McCormack S., Schmidt C., et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24 4 (2006) 417-425
28. Ackers M.L., Parekh B., Evans T.G., Berman P., Phillips S., Allen M., et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis 187 6 (2003) 879-886
29. Anton P.A., Poles M.A., Elliott J., Mao S.H., McGowan I., Lenz H.J., et al. Sensitive and reproducible quantitation of mucosal HIV-1 RNA and DNA viral burden in patients with detectable and undetectable plasma viral HIV-1 RNA using endoscopic biopsies. J Virol Methods 95 1-2 (2001) 65-79
30. Shacklett B.L., Yang O.O., Hausner M.A., Elliott J., Hultin L., Price C., et al. Optimization of methods to assess human mucosal T-cell responses to HIV infection and vaccination. J Immunol Methods 279 (2003) 17-31
31. Kozlowski P.A., Lynch R.M., Patterson R.R., Cu-Uvin S., Flanigan T.P., and Neutra M.R. Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J Acquir Immune Defic Syndr 24 4 (2000) 297-309
32. Martinez-Maza O., Crabb E., Mitsuyasu R.T., Fahey J.L., and Giorgi J.V. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol 138 11 (1987) 3720-3724
33. Jones N., Agrawal D., Elrefaei M., Hanson A., Novitsky V., Wong J.T., et al. Evaluation of antigen-specific responses using in vitro enriched T cells. J Immunol Methods 274 1-2 (2003) 139-147
34. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 71 4 (1997) 3120-3128
35. Jamieson B.D., Ibarrondo F.J., Wong J.T., Hausner M.A., Ng H.L., Fuerst M., et al. Transience of vaccine-induced HIV-1-specific CTL and definition of vaccine "response". Vaccine 24 17 (2006) 3426-3431
36. Slobod K.S., Lockey T.D., Howlett N., Srinivas R.V., Rencher S.D., Freiden P.J., et al. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis 23 2 (2004) 106-110
37. Grewal H.M., Hemming K.T., Vetvik H., Ahren C., Gjessing H.K., Sommerfelt H., et al. Measurement of specific IgA in faecal extracts and intestinal lavage fluid for monitoring of mucosal immune responses. J Immunol Methods 239 1-2 (2000) 53-62
38. Mestecky J., Moro I., Kerr M.A., and Woof J.M. Mucosal immunoglboulins. In: Mestecky J., Bienenstock J., Lamm M.E., Strober W., McGhee J.R., and Mayer L. (Eds). Mucosal immunology. 3rd ed. (2005), Elsevier Academic Press 153-181
39. McGowan I., Elliott J., Cortina G., Tanner K., Siboliban C., Adler A., et al. Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr 46 4 (2007) 417-425